Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alkaloid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Alkaloid. Displaying page 1 of 1.
    EudraCT Number: 2006-002074-22 Sponsor Protocol Number: UM2005/00201/00 Start Date*: 2006-10-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer.
    Medical condition: Brain metastases from primary non-small cell lung cancer (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011118-47 Sponsor Protocol Number: L00070IN308B0 Start Date*: 2009-04-24
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vi...
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    11.0 10055113 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) PT (Completed) IT (Completed) ES (Completed) BE (Completed) DE (Completed) AT (Completed) HU (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-002308-40 Sponsor Protocol Number: IN Morphine II Start Date*: 2005-08-19
    Sponsor Name:University of Plymouth
    Full Title: Evaluation of Intranasal (IN) Morphine Sulphate as a Paramedic Administered Analgesic for Children in the Pre-Hospital Environment
    Medical condition: This research hopes to bridge the gap between in-hospital diamorphine and pre-hospital IV morphine by developing IN morphine for administration to children between 3 and 14 years old. This will all...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001508-38 Sponsor Protocol Number: ST 200-DM-03-005 Start Date*: 2006-03-21
    Sponsor Name:SIGMA-TAU
    Full Title: Phase II Explorative Study of Acetyl-L-Carnitine (ST 200) for Vincristine-Induced Neurotoxicity in Patients With Acute Lymphoblastic Leukemia (ALL).
    Medical condition: Treatment of peripheral sensitive neuropathy vinca alkaloid chemotherapy -induced.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000846 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004004-22 Sponsor Protocol Number: 233928 Start Date*: 2018-03-16
    Sponsor Name:University of Sussex
    Full Title: A Multi-Centred, Open Label, Randomised Study Assessing the Cardiovascular Outcomes Following Treatment of White Coat Hypertension with Established Anti-Hypertensive Drugs versus Standard of Care i...
    Medical condition: White Coat Hypertension
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003216-30 Sponsor Protocol Number: 309544 Start Date*: 2005-11-14
    Sponsor Name:Schering AG
    Full Title: Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy, safety and tolerability of 4 regimes with 3 doses of ZK 219477 (16 and 12 mg/m² body ...
    Medical condition: Histologically proven metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) SI (Completed) IT (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-016879-29 Sponsor Protocol Number: IPR/22 Start Date*: 2010-01-25
    Sponsor Name:MOLMED
    Full Title: NGR015: Randomized double-blind phase III study of NGR-hTNF plus best investigator s choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma...
    Medical condition: Patients with advanced malignant pleural mesothelioma (MPM)previously treated with pemetrexed
    Disease: Version SOC Term Classification Code Term Level
    12.1 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) AT (Completed) IE (Completed) GB (Completed) NL (Completed) BE (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-010004-28 Sponsor Protocol Number: ACNS0331 Start Date*: 2010-04-14
    Sponsor Name:COG
    Full Title: ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblas...
    Medical condition: Medulloblastoom standard risk
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027107 Medulloblastoma LLT
    12.0 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003257-42 Sponsor Protocol Number: ACH-CYT-02 Start Date*: 2017-10-03
    Sponsor Name:Achieve Life Sciences Inc
    Full Title: Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers
    Medical condition: Smoking cessation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006278-13 Sponsor Protocol Number: NL24092.042.08 Start Date*: 2009-02-04
    Sponsor Name:UMCG
    Full Title: Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.
    Medical condition: patients with advanced (>5 years) Parkinson's disease and visual hallucinations.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047570 Visual hallucinations LLT
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023175-26 Sponsor Protocol Number: P_TPT_2010 Start Date*: 2011-01-14
    Sponsor Name:Leiden University Medical Center
    Full Title: Influence of Tapentadol on endogenous modulation of pain in chronic neuropathic pain patients and healthy volunteers
    Medical condition: Chronic pain patients/ mhealthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049475 Chronic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003989-18 Sponsor Protocol Number: AMR PH GL 2007 CL 001 Start Date*: 2008-04-24
    Sponsor Name:Celgene Corporation
    Full Title: A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ...
    Medical condition: Extensive or limited and sensitive or refractory SCLC after failure of first-line chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) DK (Completed) HU (Completed) NL (Completed) AT (Completed) CZ (Completed) IT (Completed) FR (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-002286-32 Sponsor Protocol Number: 6125 Start Date*: 2009-08-10
    Sponsor Name:Queen Mary Medical University of London
    Full Title: Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukae...
    Medical condition: This is a phase I/ II trial to determine the efficacy of intravenous veltuzumab and epratuzmab either individually or together in combination with chemotherapy in patients with recurrent acute lymp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003890 B precursor type acute leukaemia LLT
    9.1 10003917 B-cell type acute leukaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003232-24 Sponsor Protocol Number: AVA-PED-301 Start Date*: 2020-12-03
    Sponsor Name:Dova Pharmaceuticals, Inc.
    Full Title: A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment...
    Medical condition: Thrombocytopenia in paediatric subjects with immune thrombocytopenia for ≥6 months duration who have had an insufficient response to a previous treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043555 Thrombocytopenias HLT
    23.0 10005329 - Blood and lymphatic system disorders 10083843 Primary immune thrombocytopenia LLT
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    20.0 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) HU (Ongoing) DE (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005912-28 Sponsor Protocol Number: EGF107671 Start Date*: 2007-04-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Study EGF107671 – a Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radi...
    Medical condition: Brain metastases from ErbB2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002677-30 Sponsor Protocol Number: KFE2011.04 Start Date*: 2011-08-29
    Sponsor Name:Professor Hans Erik Johnsen, MD, DMSc, Department of Haematology, Aalborg Hospital
    Full Title: Preclinical phase 0 micro dose study to evaluate the effekt of R-CHOP chemotherapy on cellular gene-expression. - Establisment of a preclinical model for in vivo evaluation of molecular biological...
    Medical condition: Diffuse Large B-Cell Lymphoma, Mantlecell Lymphoma, Follicular Lymphoma, Primary Mediastinal Lymphoma, B-CLL if Rituximab is used as part of treatment.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    18.0 100000004864 10036712 Primary mediastinal large B-cell lymphoma NOS LLT
    18.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    18.0 100000004864 10016934 Follicular predominantly small cleaved cell lymphoma (Working Formulation) NOS LLT
    18.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000338-20 Sponsor Protocol Number: MK-7655A-021 Start Date*: 2019-06-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Tha...
    Medical condition: Treatment of bacterial infections in pediatric populations
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10071097 Beta-lactam antibiotic resistance LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Ongoing) Outside EU/EEA ES (Restarted) BG (Ongoing) GR (Ongoing) NO (Ongoing) EE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA